Detail akcie Aerovate Therap Rg online

Business Summary: Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Jade Biosciences Inc revenues was not reported. Net loss decreased 7% to $59.8M. Lower net loss reflects Research and development - Balancing val decrease of 15% to $39.5M (expense), General and administrative - Balancing v decrease of 15% to $9.4M (expense), Interest income increase of 23% to $5M (income).